close
MENU
Hot Topic Budget 25
How to guide
How to guide
Home
NBR Marketplace
The NBR List
NBR Video

Categories

General Business Investment Economics Te Ao Māori Politics Infrastructure Australia Tech & Innovation Finance Law Professional Services Primary Industries Retail Property Deals Marketing & Media Tourism Energy Luxury Property Aviation News Comings & Goings

Analysis

All Economy Matters Edwards on Politics Hunter’s Corner Last Word Margin Call On the Money Shoeshine Underarm NBR Focus

Featured

The NBR Podcast Morning Brew The Grind Entrepreneurs Your Business Beehive Banter Toil & Trouble Market Outlook Dollars & Sense Local Edge Private Bin Audio Articles Podcasts NZ Aviation News Back Issues NBR Radar (Archive) Opinion (Archive) NBR Rich List (Archive)
Hot Topic Budget 25
General Business
3 mins to read

Aussie VC investor wants liberalisation of trans-Tasman market

Australian VC law treats New Zealand as the ‘rest of the world’. It doesn’t have to be that way.

Hashan De Silva bought into Neuren at A$1 and the stock is at A$20 today on the ASX.

Lachlan Colquhoun Tue, 11 Jun 2024

Australian biotech investor Hashan De Silva would like to be free to invest as much of his venture capital fund in New Zealand as he liked, but is restricted by Australian legislation he believes should be modified.

Under the Venture Capital Act, originally passed in 2002, VC funds are only able to

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
View terms and conditions.
Individual
Group membership
NBR Marketplace

Smartphone Only Subscription

NZ$29.95 / monthly

Monthly Premium Online Subscription

NZ$49.95 / monthly

Smartphone Only Annual Subscription

NZ$299.00 / yearly

Yearly Premium Online Subscription

NZ$499.00 / yearly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$999.00 / yearly

Already have an account? Login
Lachlan Colquhoun Tue, 11 Jun 2024
Contact the Writer: lachlan@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Tags
venture capital biotech Alimetry VC Trans-Tasman

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Related News
General Business
2

A sustainable VC market needs to be trans-Tasman, says US analyst
General Business
5

Kiwi startups struggling for capital, but there are rays of hope
General Business

Kimer Med’s Series A to fund antiviral drug development
Australia

Aussie Blackbird VC fund hunts for Kiwi unicorns
Tech & Innovation

Medical device startup Alimetry appoints experienced US chair

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Related News
General Business
2

A sustainable VC market needs to be trans-Tasman, says US analyst
General Business
5

Kiwi startups struggling for capital, but there are rays of hope
General Business

Kimer Med’s Series A to fund antiviral drug development
Australia

Aussie Blackbird VC fund hunts for Kiwi unicorns
Tech & Innovation

Medical device startup Alimetry appoints experienced US chair
Aussie VC investor wants liberalisation of trans-Tasman market
General Business,
104407
true
Subscribe Login